RESIST-2: 2nd-line ART for HIV-2 Infection

Condition:   HIV-2 Infection Interventions:   Diagnostic Test: HIV-2 Genotypic Drug Resistance Testing using DBS;   Drug: 2nd line ART ( Zidovudine 300mg BID + Lamivudine 150mg BID or Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID);   Drug: 2nd line ART (Tenofovir DF 300mg QD + La mividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID + Raltegravir 400mg BID );   Drug: 2nd line ART (Tenofovir DF 300mg QD + Lamividine 300mg QD or Tenofovir DF 300mg QD + Emtricitabine 200mg QD + Darunavir 600mg BID-Ritonavir 100mg BID +Raltegravir 400mg BID) Sponsors:   University of Washington;   Clinique des Maladies Infectieuses, CHNU de Fann, Dakar, Senegal;   Centre de Sante de Ziguinchor, Casamance, Senegal;   Janssen Pharmaceutica;   Merck Sharp & Dohme Corp.;   National Institute of Allergy and Infectious Diseases (NIAID) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials